Prevention and management of hypertension and cardiovascular diseases


Cardiovascular disease (CVD), e.g., coronary heart disease (CHD), valvular diseases and complex congenital heart diseases has the highest prevalence among all diseases in China, and is also the leading cause of death in China. Several generations of physicians in FuWai hospital have been doing ground-breaking work on establishing CVD management system. In 1974, Prof. Jia-Qiang Guo carried out the first coronary artery bypass graft (CABG) surgery in China, which marked the beginning of coronary surgery in China. Prof. Run-Lin Gao, member of the Chinese Academy of Engineering, completed the first intracoronary thrombolytic therapy and the first intracoronary stent implantation in 1984 and 1992 respectively, initiated the intervention for CHD in China. Prof. Sheng-Shou Hu, member of the Chinese Academy of Engineering, completed the first off-pump CABG and the first minimally invasive thoracoscopically assisted CABG in 1996 and 1999 respectively. In 1999, Prof. Hu along with Prof. Run-Lin Gao, member of the Chinese Academy of Engineering, completed the first hybrid coronary revascularization in China, which introduced a new era of “minimally invasive hybrid” in coronary surgery. In 1976, Prof. Xiao-Dong Zhu, member of the Chinese Academy of Engineering, started the research and development of the bovine pericardial valve, and in July 1976 he completed the first domestic bioprosthetic valve replacement, which created a precedent of the clinical application of domestic bioprosthetic valves and promoted the development of heart valve surgery in China. In 1972, Prof. Jia-Qiang Guo completed the first double outlet right ventricle correction; in 1987, Prof. Guo finished the first arterial switch operation in China, and opened a new chapter of complex congenital heart defects management in China. In 1997, Prof. Qing-Yu Wu invented a new anatomic repair procedure for Ebstein anomaly. In 2004 and 2005, Prof. Sheng-Shou Hu completed world’s first double root translocation and the first hybrid treatment of newborn pulmonary atresia with intact ventricular septum, which improved China’s academic status in the complex congenital heart defect management field. Thanks to the series of “first”s and FuWai-er’s continuous exploration and innovation, the CVD management system has become intact and the treatment level of CVD in China is substantially improved.